arrow
V

Virginia Meca-Lallana

hospital de la princesa
H指数:18
被引数:1,162

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Viral immune profiles in multiple sclerosis and HIV co-infection providing insights into antiretroviral treatment-associated immuno-remodeling

多发性硬化与HIV合并感染中的病毒免疫特征,为抗逆转录病毒治疗相关的免疫重塑提供见解

2026-10-090
OAAI
Real-world siponimod use in secondary progressive multiple sclerosis: the RESYZE study

真实世界西尼莫德在继发性进展型多发性硬化中的使用:RESYZE研究

2026-08-130
PRE
How do neurologists perceive the organization and functioning of multiple sclerosis care units?

神经科医生如何看待多发性硬化护理单元的组织和运作?

2025-12-120
OA
Neurologists’ Openness to Evidence-Based Innovation in Multiple Sclerosis Care: Individual and Structural Determinants

神经科医生对多发性硬化护理中循证创新的开放性:个体和结构决定因素

2025-07-290
OA
Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis

关于治疗多发性硬化的疾病修正药物的临床试验的批判性阅读建议

2025-06-200
OAAI
Economic burden of secondary progressive multiple sclerosis: DISCOVER study

继发性进展型多发性硬化症的经济负担:DISCOVER研究

2025-04-100
OA
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis (vol 15, 1480676, 2024)
2024-12-190
OAAI
Observational study of gadolinium-enhancing lesions in MRI in patients with multiple sclerosis from the Spanish Mediterranean coast: Seasonal variability and relationship with climatic factors

西班牙地中海沿岸多发性硬化症患者MRI钆增强病灶的观察性研究:季节性变异及其与气候因素的关系

2024-12-011
PRE
Biomarkers of response to ocrelizumab in relapsing-remitting multiple sclerosis

ocrelizumab治疗复发缓解型多发性硬化反应的生物标志物

2024-11-120
OAAI
Real-World Retrospective Analysis of Alemtuzumab Outcomes in Relapsing-Remitting Multiple Sclerosis: The LEMCAM Study
2024-02-281
OAAI
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
2022-05-0610
OAAI
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder
2022-05-027
OAAI
Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology
2022-03-213
OAAI
SARS-CoV-2 Infection in Multiple Sclerosis Results of the Spanish Neurology Society Registry
2021-09-0128
OAAI
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

一组原发性进行性多发性硬化症患者的疾病活动,认知,情绪,污名和就业结果的短期数据 (UPPMS研究)

2021-05-019
PREAI
Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS
2021-03-0441
OAAI
Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study
2020-11-236
PREAI